45 results on '"Seif, Alix"'
Search Results
2. Approach for defining human adenovirus infection and disease for central review adjudication in clinical studies
3. Absolute neutrophil count clinical trial eligibility criteria for pediatric oncology phase I and phase I/II trials by sponsorship
4. Applying machine learning to identify pediatric patients with newly diagnosed acute lymphoblastic leukemia using administrative data
5. Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia
6. Leveraging machine learning to identify acute myeloid leukemia patients and their chemotherapy regimens in an administrative database
7. Absolute lymphocyte count recovery following initial acute myelogenous leukemia therapy: Implications for adoptive cell therapy
8. Incidence and risk factors for hypoglycemia during maintenance chemotherapy in pediatric acute lymphoblastic leukemia
9. Early stool microbiome and metabolome signatures in pediatric patients undergoing allogeneic hematopoietic cell transplantation
10. Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective
11. Presentation acuity, induction mortality, and resource utilization in infants with acute leukemia
12. Identifying relapses and stem cell transplants in pediatric acute lymphoblastic leukemia using administrative data: Capturing national outcomes irrespective of trial enrollment
13. Transient atypical monocytosis after α/β T‐cell‐depleted haploidentical hematopoietic stem cell transplantation
14. Outcomes of human adenovirus infection and disease in a retrospective cohort of pediatric solid organ transplant recipients
15. Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events
16. Comparable on-therapy mortality and supportive care requirements in Black and White patients following initial induction for pediatric acute myeloid leukemia
17. Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database
18. The epidemiology of rasburicase use in paediatric patients with acute lymphoblastic leukaemia and non‐Hodgkin lymphoma
19. Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232
20. Nutritional risk factors predict severe acute graft-versus-host disease and early mortality in pediatric allogeneic hematopoietic stem cell transplantation
21. Outcomes of matched sibling donor bone marrow transplantation in children using single-agent calcineurin inhibitors as prophylaxis for graft versus host disease
22. Complications preceding early deaths in Black and White children with acute myeloid leukemia
23. IFN-γ directly inhibits murine B-cell precursor leukemia-initiating cell proliferation early in life
24. Using electronic medical record data to report laboratory adverse events
25. The role of acuity of illness at presentation in early mortality in black children with acute myeloid leukemia
26. Low rates of pregnancy screening in adolescents before teratogenic exposures in a national sample of children's hospitals
27. Early discharge as a mediator of greater ICU ‐level care requirements in patients not enrolled on the AAML 0531 clinical trial: a Children's Oncology Group report
28. Supportive care utilization and treatment toxicity in children with Down syndrome and acute lymphoid leukaemia at free-standing paediatric hospitals in the United States
29. Resource Utilization and Toxicities After Carboplatin/Etoposide/Melphalan and Busulfan/Melphalan for Autologous Stem Cell Rescue in High-Risk Neuroblastoma Using a National Administrative Database
30. A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia
31. Comparison of in-patient costs for children treated on the AAML0531 clinical trial: A report from the Children's Oncology Group
32. Comparison of administrative/billing data to expected protocol-mandated chemotherapy exposure in children with acute myeloid leukemia: A report from the Children's Oncology Group
33. Dexrazoxane exposure and risk of secondary acute myeloid leukemia in pediatric oncology patients
34. Establishing a high‐risk neuroblastoma cohort using the pediatric health information system database
35. Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia
36. Zoonotic infections in pediatric patients with acute leukemia
37. Induction mortality, ATRA administration, and resource utilization in a nationally representative cohort of children with acute promyelocytic leukemia in the United States from 1999 to 2009
38. Induction mortality and resource utilization in children treated for acute myeloid leukemia at free-standing pediatric hospitals in the United States
39. Assembly of a cohort of children treated for acute myeloid leukemia at free‐standing children's hospitals in the United States using an administrative database
40. Dexrazoxane use in pediatric patients with acute lymphoblastic or myeloid leukemia from 1999 and 2009: Analysis of a national cohort of patients in the pediatric health information systems database
41. Secondary adrenal insufficiency in an infant after intrathecal triple chemotherapy
42. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma
43. Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS)
44. Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome
45. Association of the social disorganization index with time to first septic shock event in children with acute myeloid leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.